NRI-CAI Combination Therapy for Central Hypoventilation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity hypoventilation syndrome (OHS) and obesity-related sleep hypoventilation (ORSH) are inadequate, with positive air pressure therapy having low adherence and no approved pharmacologic options, and existing treatments do not address all pathogenic contributors to these conditions.
Innovation Solution
Administering a combination of a norepinephrine reuptake inhibitor (NRI), such as atomoxetine, and a carbonic anhydrase inhibitor (CAI), like acetazolamide, to stimulate ventilation and improve respiratory function in patients with central hypoventilation syndromes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If positive air pressure therapy is used to treat obesity hypoventilation syndrome, then ventilation is improved, but adherence is low
Solution Approach 1:
The patent replaces the mechanical positive air pressure therapy system with a pharmacological solution. By using a combination of norepinephrine reuptake inhibitors and carbonic anhydrase inhibitors, the treatment eliminates the need for continuous mechanical ventilation support, thereby improving patient adherence while maintaining effective ventilation stimulation.
Solution Approach 2:
The patent changes the treatment parameter from mechanical (air pressure) to biochemical (pharmacological agents). The combination of NRIs and CAIs modifies the physiological parameters of respiratory drive and ventilation through chemical mechanisms, providing a more sustainable and adherent treatment approach compared to mechanical therapy.
2Device complexity
If no pharmacologic options are available, then treatment simplicity is maintained, but treatment effectiveness is insufficient
Solution Approach 1:
The patent merges two pharmacological mechanisms into a single treatment approach: norepinephrine reuptake inhibitors that stimulate respiratory drive and carbonic anhydrase inhibitors that enhance ventilation. This combination provides effective pharmacologic treatment for obesity hypoventilation syndrome while maintaining a relatively simple treatment regimen compared to complex mechanical therapy.
3Object-affected harmful factors
If existing treatments are used, then some symptoms are addressed, but not all pathogenic contributors are treated
Solution Approach 1:
The patent employs a multi-functional pharmacological approach where the combination of NRI and CAI addresses multiple pathogenic contributors to obesity hypoventilation syndrome simultaneously. The NRI component targets respiratory drive stimulation while the CAI component enhances ventilation and addresses associated metabolic effects, providing comprehensive treatment that covers multiple aspects of the disease pathology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of NRIs and CAIs effectively reduces symptoms of hypoventilation, including snoring, apneas, and breathlessness, and improves alveolar ventilation, offering a potential therapeutic benefit for OHS and ORSH that complements existing treatments.
Implementation Method 1
a norepinephrine reuptake inhibitor (NRI)... to stimulate ventilation
Implementation Method 2
a carbonic anhydrase inhibitor (CAI)... to stimulate ventilation
Data Source
AI summary
Pharmaceutical compositions comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a carbonic anhydrase inhibitor (CAI) and methods of treating conditions associated with central hypoventilation are described herein.